Table 1:
Statin use in SAMS group versus statin-tolerant group
| Variable, N(%) or Mean ± SD |
SAMS Group (n=634) |
Statin-Tolerant Group (n=114) |
P-value |
|---|---|---|---|
| Age at starting statin, yr | 58.0 ± 10.9 (n=573)a | 58.1 ± 11.9 (n=79)a | 0.90 |
| Sex, Male | 340 (53.6) | 52 (46.4) | 0.16 |
| Statin used | |||
| Atorvastatin | 254 (40.1) | 69 (60.5) | 0.0001b |
| Simvastatin | 113 (17.8) | 11 (9.6) | |
| Rosuvastatin | 68 (10.7) | 5 (4.4) | |
| Lovastatin | 20 (3.2) | 6 (5.3) | |
| Pravastatin | 38 (6.0) | 5 (4.4) | |
| Two statins (switched from one to another) | 129 (20.4) | 10 (8.8) | |
| Other (pitavastatin, fluvastatin or cerivastatin) | 12 (1.8) | 8 (7.0) | |
| Statin dose | |||
| 5 mg | 29 (4.6) | 4 (3.5) | 0.049 |
| 10 mg | 169 (26.7) | 41 (36.0) | |
| 20 mg | 183 (28.9) | 25 (21.9) | |
| 40 mg | 138 (21.8) | 19 (16.7) | |
| 80 mg | 36 (5.6) | 12 (10.5) | |
| Other | 79 (12.4) | 13 (11.4) | |
| Stopped statin therapy | 538 (84.9) | 5 (4.4) | 0.0001 |
| Age stopped statin, yr | 59.9 ±11.0 (n=262) | 59.5±5 (n=6) | |
| Those who stopped statins with known interval (n=424) | |||
| ≤30 days | 47 (11.1) | 0 (0.0) | |
| 30–180 days | 98 (23.1) | 0 (0.0) | |
| ≥180 days | 279 (65.8) | 5 (4.4) | |
a
Age at start of statin therapy was missing for some participants.
b
P-value calculated excluding ‘other’ or missing statin type.
SAMS: statin-associated muscle symptoms; mg: milligram